SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Averion International Corp. (OTCBB:AVRO), a clinical research organization (CRO) specializing in oncology, medical devices, dermatology and nephrology, today announced financial results for the three months ended March 31, 2007. In November 2005, Averion International Corp.’s predecessor company, IT&E International Group Inc., merged with Millennix, Inc., and on July 31, 2006 completed a series of transactions under the Agreement and Plan of Merger announced on July 6, 2006 with Averion Inc. Shortly after, the Company was renamed Averion International Corp. following approval by the U.S. Securities and Exchange Commission (SEC) and NASDAQ.
